Floatz logo

Tislelizumab

Anaplastic Large Cell Lymphoma, ALK-negative

BeiGenemonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Anaplastic Large Cell Lymphoma, ALK-negative cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
ETOPOSIDE
City of Hope Medical Center
Phase 4BB
Ifosfamide
Shandong Provincial Hospital
Phase 4BB
PREDNISONE TABLETS
Shanghai Jiao Tong University School of Medicine
Phase 4BB
Inno-206
City of Hope Medical Center
Phase 4BB

View all 27 →

Same molecule, other indications

Tislelizumab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
Hepatic Metastasis of Pancreatic CancerDormant
BB
Indicative ·
69 / 100
View asset →
Primary Peritoneal Cavity CancerDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →